Co-occurrence of ESR1m with other alterations

Along with the Oncology Brothers, Paolo Tarantino, MD, explores how ESR1 mutations (ESR1m) frequently co-occur with other genetic alterations such as PIK3CA, TP53, and HER2-low expression, and discusses the ongoing research into the prognostic significance of these co-occurring mutations in metastatic breast cancer.

EP: 1.Overview of Phase 3 EMERALD Study of Elacestrant for ER+, HER2–- MBC

EP: 2.Incidence of ESR1 mutations and best practices for testing

Now Viewing

EP: 3.Co-occurrence of ESR1m with other alterations

How frequently are ESR1m found to co-occur with other alterations (eg, PIK3CA, TP53, or HER2-low expression)?

Do we know the significance of co-occurring mutations in terms of prognosis?

Recent Videos